Idoxifene Explained

Idoxifene (INN, USAN, BAN) (former developmental code names CB-7432, SB-223030), also known as pyrrolidino-4-iodotamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group which was under development for the treatment of breast cancer and postmenopausal osteoporosis but was never marketed.^{[1] [2] [3]} It reached phase III clinical trials for postmenopausal osteoporosis and phase II clinical trials for breast cancer before development was discontinued in 1999 due to insufficient effectiveness in both cases.

Chemistry

Synthesis

A large-scale chemical synthesis of idoxifene has been devised.^[4]

Notes and References

1. Web site: Idoxifene . AdisInsight . Springer Nature Switzerland AG .
2. Book: Miller WR, Ingle JN . Endocrine Therapy in Breast Cancer. 8 March 2002. CRC Press. 978-0-203-90983-6. 58–.
3. McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, Foster AB . Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent . Journal of Medicinal Chemistry . 32 . 12 . 2527–2533 . December 1989 . 2585441 . 10.1021/jm00132a006 .
4. McCague R, Potter GA, Jarman M . An Efficient, Large-Scale Synthesis of Idoxifene ((E)-1-(4-(2-(N-Pyrrolidino) ethoxy) phenyl)-1-(4-Iodophenyl)-2-phenyl-1-butene) . Organic Preparations and Procedures International. 26. 3. 1994. 343–346. 0030-4948. 10.1080/00304949409458432.